During the 2018 outbreak of Ebola, Regeneron quickly developed a promising monoclonal antibody triplet therapy that’s now under review by the FDA. Now, amid the ongoing coronavirus pandemic, the biotech is at it again, planning to advance a antibody cocktail into the clinic by early summer.